Abstracts tagged "Myositis"

Abstract Number: 2237 • ACR Convergence 2022
Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Idiopathic Inflammatory Myopathy: Results of the 24-Week Double-Blind and 28-Week Open-Label Periods
Rohit Aggarwal¹, Ingrid Lundberg², Yeong-Wook Song³, Aziz Shaibani⁴, Victoria Werth⁵ and Michael Maldonado⁶, ¹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ²Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ³Seoul National University, Seoul, Republic of Korea, ⁴Nerve and Muscle Center of Texas, Houston, TX, ⁵Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: A 52-week (wk), randomized, placebo (PBO)-controlled phase 3 trial of subcutaneous (SC) abatacept (ABA) and standard of care (SOC) was performed in patients (pts)…
Abstract Number: 0157 • ACR Convergence 2022
Brepocitinib for the Treatment of Dermatomyositis: Pharmacologic and Clinical Rationale
Rohit Aggarwal¹, Brendan Johnson², Jolie Feldman³, Austin Gromatzky⁴ and Paul N Mudd Jr.², ¹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ²Priovant Therapeutics, Durham, NC, ³Priovant Therapeutics, New York, NY, ⁴Priovant Therapeutics, Washington, DC
Background/Purpose: Brepocitinib is a novel, orally available, TYK2/JAK1 inhibitor in Phase 3 development for the treatment of dermatomyositis (DM), a chronic immune-mediated disease of the…
Abstract Number: 0180 • ACR Convergence 2022
Alterations of Nutritional Status in Patients with Idiopathic Inflammatory Myopathies and Their Association with Disease-related Features
Sabína Oreská¹, Hana Storkanova¹, Maja Spiritovic², Barbora Hermankova², Michal Vrablík³, Karel Pavelka⁴, Ladislav Šenolt⁵, Heřman Mann¹, Jiří Vencovský⁵ and Michal Tomcik¹, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Systemic inflammation, involvement of the gastrointestinal tract, and glucocorticoid (GC) treatment in idiopathic inflammatory myopathies (IIM) can have a negative impact on nutrition and…
Abstract Number: 1865 • ACR Convergence 2022
Internet-based Enrollment for Myositis Studies Utilizing Patient Self-reported Diagnostic Criteria
Raisa Lomanto Silva¹, Silvia Martinez Laverde¹, Siamak Moghadam-Kia¹, Nicole Neiman², Dana Ascherman³, Chester Oddis³ and Rohit Aggarwal⁴, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Division of Rheumatology and Clinical Immunology, Department of Medicine, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Recruitment is a major challenge in myositis clinical studies, which is hindered by the rarity and heterogeneity of the disease. Internet-based clinical studies using…
Abstract Number: 2238 • ACR Convergence 2022
Performance of the 2016 ACR/EULAR Myositis Response Criteria in Adult Dermatomyositis and Polymyositis Therapeutic Trials and Consensus Profiles
Didem Saygin¹, Hanna Kim², Christian Douglas³, Brian Erman³, Jesse Wilkerson³, john mcgrath³, Chester Oddis⁴, Ingrid Lundberg⁵, Anthony Amato⁶, Ignacio Garcia-De La Torre⁷, Hector Chinoy⁸, David Fiorentino⁹, Lorinda Chung⁹, Yeong-Wook Song¹⁰, Katalin Danko¹¹, Frederick Miller¹², Nicola Ruperto¹³, Jiří Vencovský¹⁴, Rohit Aggarwal¹⁵ and Lisa G Rider¹², ¹University of Chicago, Chicago, IL, ²Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ³Social and Scientific Systems, Inc., Durham, NC, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁶Harvard University, Boston, MA, ⁷Centro de Est. de Inv. Bas. y Clinica, S.C., Guadalajara, Mexico, ⁸The University of Manchester, Sale, United Kingdom, ⁹Stanford University, Stanford, CA, ¹⁰Seoul National University, Seoul, Republic of Korea, ¹¹*Deceased, Debrecen, Hungary, ¹²Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, ¹³IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, ¹⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹⁵Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The ACR/EULAR myositis response criteria (MRC) were developed as a composite continuous measure (Total Improvement Score (TIS)) using absolute percent changes (abs%) in 6…
Abstract Number: 0158 • ACR Convergence 2022
Effect of Type I IFN on Mitochondria and Muscle Weakness in Myositis
Melissa Morales, Joanna Parkes, Sabrina Narvesen and Rita Spathis, Department of Pharmaceutical Sciences, Binghamton University, Binghamton, NY
Background/Purpose: Muscle weakness is a hallmark of autoimmune myositis. The mechanisms that contribute to muscle weakness are currently unknown. The observed ineffectiveness after immunomodulatory treatment…
Abstract Number: 0952 • ACR Convergence 2022
Pregnancy Course and Outcomes of Patients with Polymyositis and Dermatomyositis (PM/DM) in Our Institution
Rina Mino¹, Hiromi Shimada², Risa Wakiya², shusaku nakashima³, Mikiya Kato², taichi miyagi⁴, Yusuke Ushio⁵, Kanako Chujo⁶, Tomohiro Kameda² and Hiroaki Dobashi⁷, ¹Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Miki-cho, Kita-gun, Japan, ²Kagawa University, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ⁴Kagawa University, Kidagun, Japan, ⁵Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, ⁶Kagawa University, Miki, Kita District, Kagawa, Japan, ⁷Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Kagawa, Japan
Background/Purpose: The purpose of this study is to determine the association between changes in disease activity during pregnancy and pregnancy outcome by analyzing a case…
Abstract Number: 1866 • ACR Convergence 2022
Polymyositis/Dermatomyositis Readmissions: Analysis of the Nationwide Readmission Database
Ehizogie Edigin¹, Amy Trang², Sandhya Shri Kannayiram³, Chinenye Osuorji⁴, Christopher Hino¹, Precious Eseaton⁵, Solomon Anighoro⁶, Augustine Manadan² and Christina Downey⁷, ¹Loma Linda University Health, Loma Linda, CA, ²Rush University Medical Center, Chicago, IL, ³John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ⁴Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY, ⁵University of South Wales, Cardiff, Wales, United Kingdom, ⁶St. Helens and Knowsley Teaching hospitals NHS Trust, Prescot, England, United Kingdom, ⁷Loma Linda University Medical Center, Redlands, CA
Background/Purpose: Polymyositis (PM)/ Dermatomyositis (DM) is a chronic immune-mediated myositis characterized by relapses that can lead to frequent hospitalizations. There is a scarcity of national…
Abstract Number: 2241 • ACR Convergence 2022
Autoantibodies and Damage in Patients with Idiopathic Inflammatory Myopathies: A Longitudinal Multicenter Study from the EuroMyositis International Network
Fabricio Espinosa-Ortega¹, Karin Lodin², Marie Holmqvist¹, Maryam Dastmalchi³, Angela Ceribelli⁴, Jiri Venkovsky⁵, Hector Chinoy⁶, Louise Diederichsen⁷, Samuel Shinjo⁸, Ingrid Lundberg⁹ and Helene Alexanderson¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska University hospital, Huddinge, Sweden, ³Karolinska University Hospital, Stockholm, Sweden, ⁴Humanitas Research Hospital, Humanitas University, Rozzano (MI) Italy, Borgo San Giacomo, Italy, ⁵Charles Univ Prague, Inst Rheumatol, Prague, Czech Republic, Prague, Czech Republic, ⁶The University of Manchester, Sale, United Kingdom, ⁷Copenhagen University Hospital, Rigshospitalet, Dragør, Denmark, ⁸Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, ⁹Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) may harbor autoantibodies that are associated with well-defined clinical phenotypes. The association of these autoantibodies with level of…
Abstract Number: 0159 • ACR Convergence 2022
B Cell Phenotype in Adult Patients with Idiopathic Inflammatory Myositis (IIM) Before and After Belimumab
Tam Quach¹, Anne Davidson² and Galina Marder³, ¹Feinstein Institute for Medical Research, Manhasset, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY, ³Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
Background/Purpose: Recent observations suggest the importance of the BAFF pathway in the pathogenesis of Idiopathic Inflammatory Myositis (IIM). Elevated serum levels of circulating BAFF in…
Abstract Number: 0991 • ACR Convergence 2022
Prior Use of Autoimmune Disease Treatments Among Patients with Systemic Lupus Erythematosus, Rheumatoid Arthritis, or Myositis Hospitalized with COVID-19
Cassandra Calabrese¹, Gelareh Atefi², Kristin Evans³, Meghan Moynihan³, Liisa Palmer³ and Sandra Sze-jung Wu⁴, ¹Cleveland Clinic Foundation, Cleveland Heights, OH, ²AstraZeneca, Wilmington, DE, ³Merative, Cambridge, MA, ⁴AstraZeneca, Hockessin, DE
Background/Purpose: To compare use of autoimmune disease treatments between patients with and without severe COVID-19 (COVID) in cohorts of patients with systemic lupus erythematosus (SLE),…
Abstract Number: 1867 • ACR Convergence 2022
YKL-40-mediated Inflammatory Pathogenesis Common to Polymyositis / Dermatomyositis
Kazuteru Noguchi¹, Tetsuya Furukawa², Takahiro Yoshikawa¹, Mai Morimoto¹, Teppei Hashimoto², Naoto Azuma³ and Kiyoshi Matsui², ¹Hyogo Medical University, Nishinomiya, Japan, ²Hyogo college of Medicine, Nishinomiya, Japan, ³Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan
Background/Purpose: YKL-40 is a chitinase-like protein that is associated with interstitial lung disease in patients with polymyositis (PM)/dermatomyositis (DM) but not with myositis. Myositis pathogenesis…
Abstract Number: 2242 • ACR Convergence 2022
Metabolomics-based Identification of Metabolic Dysfunction in Inclusion Body Myositis
Jemima Albayda¹, Cissy Zhang¹, Pratik Khare¹, Brittany Adler¹, Erika Darrah¹, Lisa Christopher-Stine¹, Thomas E Lloyd² and Anne Le¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Sporadic Inclusion Body Myositis (IBM) is the most common myopathy over the age of 50 and is currently refractory to treatment. The pathogenesis of…
Abstract Number: L07 • ACR Convergence 2021
Depletion of KLRG1+ T Cells in a First-in-human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM)
Niti Goel¹, Dulce Soler-Ferran², Monette Coutreau², Jorge Escobar³, Kate Courtemanche², Merrilee Needham⁴ and Steven Greenberg⁵, ¹Abcuro, Inc.; Duke University, Durham, NC, ²Abcuro, Inc., Newton, MA, ³Abcuro, Inc., Hayward, CA, ⁴Perron Institute, Murdoch University, Perth, Australia, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Inclusion body myositis (IBM), a relentlessly progressive autoimmune skeletal muscle disease, has no effective available pharmacological therapy. A prominent feature of IBM on microscopy…
Abstract Number: 0694 • ACR Convergence 2021
Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Fiber Necroptosis and Muscle Inflammation and Ameliorates Muscle Weakness in Experimental Polymyositis
Mari Kamiya¹, Fumitaka Mizoguchi¹, Hirokazu Sasaki², Natsuka Umezawa¹ and Shinsuke Yasuda³, ¹Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ³Tokyo Medical and Dental University (TMDU), Tokyo, Japan
Background/Purpose: While glucocorticoids (GC) are the cornerstone of the treatment for polymyositis (PM), GC-induced myopathy is inevitable, which deteriorates muscle weakness. Therefore, novel therapeutic strategy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].